THOR MEDICAL |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.056 NOK | +2.52% |
|
-0.38% | -18.14% |
| Feb. 28 | Transcript : Thor Medical ASA, H2 2023 Earnings Call, Feb 28, 2024 | |
| Feb. 14 | Thor Medical ASA Announces CEO Changes | CI |
| Sales 2022 | - | Sales 2023 | - | Capitalization | 301M 3.27B |
|---|---|---|---|---|---|
| Net income 2022 | -311M -3.38B | Net income 2023 | -26M -282M | EV / Sales 2022 * | - |
| Net cash position 2022 | 98.56M 1.07B | Net cash position 2023 | 41.77M 454M | EV / Sales 2023 | - |
| P/E ratio 2022 * |
-
| P/E ratio 2023 |
-8.49
x | Employees | 2 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 36.07% |
More Fundamentals
* Assessed data
More news
Latest transcript on Thor Medical
More news
| 1 day | +2.52% | ||
| 1 week | -0.38% | ||
| Current month | -0.38% | ||
| 1 month | +3.94% | ||
| 3 months | -5.71% | ||
| 6 months | -16.85% | ||
| Current year | -18.14% |
1 week
1.02
1.10
1 month
0.961.53
Current year
0.851.53
1 year
0.852.30
3 years
0.852.30
5 years
0.852.30
10 years
0.852.30
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-03 | 1.056 | +2.52% | 107 857 |
| 24-05-02 | 1.03 | -2.83% | 90,960 |
| 24-04-30 | 1.06 | +0.95% | 333,202 |
| 24-04-29 | 1.05 | -2.78% | 131,080 |
| 24-04-26 | 1.08 | +1.89% | 153,183 |
Real-time Oslo Bors, May 03, 2024 at 10:45 am EDT
More quotes
Thor Medical ASA, formerly Nordic Nanovector ASA, is a Norway-based biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics for hematological cancers. Its main product is Betalutin, a CD37-targeting radio-immunoconjugate designed to advance the treatment of non-Hodgkin lymphoma (NHL). Betalutin uses monoclonal antibodies to attack the cancer cells in two ways, first as an immunotherapy and secondly as a targeting agent for a radioactive payload and is a combination of radiation therapy and immunotherapy. The Company is also leveraging its expertise in radionuclides and CD37-targeting antibodies, along with partners, to build a pipeline of biopharmaceuticals for a range of haematological cancers.
Calendar
2024-08-29
- Q2 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -18.14% | 21.9M | |
| -1.43% | 103B | |
| +8.96% | 101B | |
| +4.40% | 23.07B | |
| -12.15% | 22.23B | |
| -4.36% | 18.05B | |
| -39.98% | 17.18B | |
| -10.04% | 16.94B | |
| +6.79% | 14.07B | |
| +38.61% | 12.35B |
- Stock Market
- Equities
- NANOV Stock
